Drugmaker Pfizer tops Street 2Q forecasts, raises forecast

Drugmaker Pfizer tops Street 2Q forecasts, raises forecast


1 photo
Save Story
Leer en español

Estimated read time: 2-3 minutes

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (AP) — Pfizer's second-quarter earnings fell 10 percent, as the largest U.S. drugmaker absorbed revenue hits from a stronger U.S. dollar and the loss of patent protection for some key products. But the maker of Viagra and the painkiller Celebrex topped expectations for the quarter and raised its 2015 forecast.

Shares of the New York company climbed Tuesday before the market opened.

Pfizer also raised its earnings forecast. The company now expects 2015 adjusted earnings of $2.01 to $2.07 per share, up from its previous forecast for $1.95 to $2.05 per share.

Analysts forecast, on average, earnings of $2.06 per share, according to FactSet.

In the second quarter, Pfizer Inc.'s earnings fell to $2.63 billion from $2.91 billion. Earnings, adjusted for one-time gains and costs, totaled 56 cents per share in the most recent quarter.

The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 51 cents per share.

Revenue fell 7 percent to $11.85 billion, but that still topped average expectations for $11.41 billion.

Pfizer said revenue grew 1 percent in the quarter, excluding the impact of foreign exchange rates. Worldwide revenue from Celebrex sank 71 percent to $224 million, as generic competition in the U.S. market ate away at sales. Competition from cheaper, generic alternatives also hit the antibiotic Zyvox, which saw sales drop 26 percent to $259 million.

Sales of the world's top-selling vaccine, Prevnar 13, grew 37 percent to $1.5 billion to help balance those hits.

Pfizer shares climbed 46 cents to $34.80 in premarket trading.

Shares of the drugmaker, a company used in calculating in the Dow Jones industrial average, have climbed 10 percent since the beginning of the year, while the Standard & Poor's 500 index has stayed nearly flat. The stock has risen 14 percent in the last 12 months.

_____

Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PFE at http://www.zacks.com/ap/PFE

_____

Keywords: Pfizer, Earnings Report, Priority Earnings

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Photos

Most recent Business stories

Related topics

Business
The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast